Accredo passes muster with OIG

Wednesday, August 30, 2017

WASHINGTON – Accredo Health Group has properly billed Medicare for inhalation drugs, according to a report from the Office of Inspector General. The review follows the inclusion of inhalation drugs in the top 20 DME products with the highest improper payment rates for calendar years 2014-15. Accredo is the first of three providers that will undergo reviews by the OIG. Medicare paid about $1.3 billion for inhalation drugs during 2014-15, with Accredo receiving 26% of payments. The OIG reviewed a random sample of 100 claim lines from a pool of 28,718 claim lines for inhalation drugs. For each sample, the OIG provided copies of the supporting documentation to a medical review contractor to determine whether or not inhalation drugs were properly billed.